A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

F. Patti, M. P. Amato, M. Filippi, P. Gallo, M. Trojano, G. C. Comi

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN'. Together they form a unique fingerprint.

Medicine & Life Sciences